Corporate | 30 September 2021 18:00
|
DGAP-News: ABIVAX
/ Key word(s): Half Year Report
Abivax announces the release of its 2021 half-year financial report PARIS, France, September 30, 2021 – 6:00 pm (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2021 half-year financial report. This document is available in electronic version on the website of the company ( www.abivax.com – “Investors” ) and on the website of the French financial markets authority, AMF ( www.amf-france.org ). *****
About Abivax (www.abivax.com)
30.09.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
|